FNA - FDA clears Paragon 28's R3ACT Stabilization System

Paragon 28 (NYSE:FNA) perks up 1.4% premarket after announcing that the FDA has given 501(k) marketing clearance to its R3ACT Stabilization System. The R3ACT Stabilization System is expected to commercially launch in early 2022. The addition of the R3ACT Stabilization System bolsters Paragon 28's ankle fracture and syndesmotic product offering, which includes the Gorilla Ankle Fracture Plating System, Gorilla Pilon Plating System, Mini-Monster Screw System, and R3LEASE Stabilization System. FNA made U.S. debut recently in October 2021, at IPO price of $16/share.

For further details see:

FDA clears Paragon 28's R3ACT Stabilization System